However, it is unlikely to be bortezomib’s critical mechanism of action because other NF-κB pathway inhibitors, like IκB kinase inhibitors, cannot kill MM cells as effectively as bortezomib [104]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.